Advertisement

Role of Preoperative Therapy in High-Risk Breast Cancer: Review

  • J. Ragaz

Abstract

Preoperative chemotherapy combines appealing theoretical concepts of tumor biology and therapy, linking the postsurgical behavior of metastases with a potentially beneficial effect of the systemic chemotherapy given before the definitive surgery. There is evidence from experimental and some clinical studies indicating enhancement of cell kinetics after noncurative cytoreduction [8, 12–14, 2b, 53, 55]. According to some data, these changes are deleterious to the host, and a reduction of the survival was documented compared with animals without cytoreduction [12, 53]. Enhancement of the metastatic potential, and of the systemic spread of the residual clones, is suspected, and according to some data, may be improved by preoperative chemotherapy [5, 12]. Although preoperative chemotherapy has been used for several years routinely in head and neck tumors [16] and osteosarcomas [48], attempts at its implementation as a conceptually new approach have started recently for other tumors [15, 22, 42, 56] as seen from several international conventions on neoadjuvant therapy held over the last few years [22, 24, 42, 56].

Keywords

Breast Cancer Advanced Breast Cancer Preoperative Chemotherapy Postoperative Chemotherapy Preoperative Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arnold DJ, Lesnick GJ (1979) Survival following mastectomy for stage III breast cancer. Am J Surg 137: 362–6PubMedCrossRefGoogle Scholar
  2. 2.
    Bonadonna G, Verennasi U, Brambilla C (1989) Primary CMF can avoid mastectomy in tumors more than 3 cms. Proc Am Soc Clin Oncol 8: 20Google Scholar
  3. 3.
    Chauvergne J, Durand M, Mauriac L et al. (1989) Randomized trial comparing mastectomy plus or minus adjuvant chemotherapy versus first line chemotherapy followed by adapted locoregional treatment for operable breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 225–231Google Scholar
  4. 4.
    Clunet J (1910) Recherches expérimentales sur les tumeurs malignes. Steinhil, ParisGoogle Scholar
  5. 5.
    Corbett TH, Griswold DP Jr, Roberts BJ et al. (1981) Cytotoxic adjuvant therapy and the experimental model. In: Stoll BA (ed) Systemic therapy in breast cancer, vol 4. Heinemann Medical, London, pp 204–243Google Scholar
  6. 6.
    De Lena M, Varini M, Zucali R et al. (1981) Multi model treatment for locally advanced breast cancer. Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4: 229–236PubMedGoogle Scholar
  7. 7.
    De Lena M, Zucali R, Viganotti G et al. (1978) Combined chemotherapy-radiotherapy approach in locally advanced (T3B-T4) breast cancer. Cancer Chemother Pharmacol 1: 53–59PubMedCrossRefGoogle Scholar
  8. 8.
    DeWys WD (1972) Studies correlating the growth rate of the tumor and its metastases and providing evidence for tumor related systemic growth retarding factors. Cancer Res 32: 374–379PubMedGoogle Scholar
  9. 9.
    Dressier L, Auclerc G, Owens M et al. (1987) DNA flow cytometry predicts for relapse in node negative breast cancer patients. Proc Am Soc Clin Oncol 6: 57Google Scholar
  10. 10.
    Emerman JT (1989) In vitro predictive sensitivity testing in the therapeutic assessment of breast cancer: In: Ragaz J, Ariel IM (eds) High risk breast cancer - Diagnosis. Springer Berlin Heidelberg New York, pp 345–362Google Scholar
  11. 11.
    Fisher B, Ravdin RG, Ausman RK et al. (1968) Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 168: 337–356PubMedCrossRefGoogle Scholar
  12. 12.
    Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and the chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492PubMedGoogle Scholar
  13. 13.
    Fisher B, Gunduz N, Coyle J et al. (1989) Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 49: 1996–2002PubMedGoogle Scholar
  14. 14.
    Fisher B, Saffer E, Rudock C et al. (1989) Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 49: 2002–2005PubMedGoogle Scholar
  15. 15.
    Frei E III (1982) Clinical cancer research: an embattled species. Cancer 50: 1979–1992PubMedCrossRefGoogle Scholar
  16. 16.
    Frei E III, Miller D, Clark JR et al. (1986) Clinical and scientific considerations in preoperative (neoadjuvant) chemotherapy. In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New York, pp 1–6CrossRefGoogle Scholar
  17. 17.
    Freshney RI (1985) Induction of differentiation in neoplastic cells. Anticancer Res 5: 111–130PubMedGoogle Scholar
  18. 18.
    Hedley DW, Rugg CA, Ng ABP et al. (1984) Influence of cellular DNA content on disease free survival of stage II breast cancer patients. Cancer Res 44: 5395–5398PubMedGoogle Scholar
  19. 19.
    Hortobagyi GN, Blumenschein GR, Spanos W et al. (1983) Multimodal treatment of locally advanced breast cancer. Cancer 51: 763–768PubMedCrossRefGoogle Scholar
  20. 20.
    Hortobagyi GN, Buzdar AU, Ames FC et al. (1989) Neoadjuvant chemotherapy in the management of advanced primary carcinoma of the breast. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy 2nd international congress. Libbey, Paris, pp 137–143Google Scholar
  21. 21.
    Hortobagyi GN, Frye D, Ames F et al. (1989) Quantitation of downstaging after neoadjuvant chemotherapy for primary breast cancer. Proc Am Soc Clin Oncol 8: 23Google Scholar
  22. 22.
    Jacquillat C, Weil M, Khayat D (eds) (1986) Neoadjuvant chemotherapy, 1st international congress. Libbey, ParisGoogle Scholar
  23. 23.
    Jacquillat C, Baillet F, Auclerc G et al. (1989) Preoperative (neoadjuvant) chemotherapy and radiotherapy in breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 129– 137Google Scholar
  24. 24.
    Jacquillat C, Weil M, Khayat D (1989) Neoadjuvant chemotherapy, 2nd international congress. Libbey, ParisGoogle Scholar
  25. 25.
    Kute TE, Muss HP, Hopkins N et al. (1985) Relationship of flow cytometry result to clinical and steroid receptor status in human breast cancer. Breast Cancer Res Treat 6: 113–121PubMedCrossRefGoogle Scholar
  26. 26.
    Lange PH, Hekmat K, Bosl G et al. (1980) Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 45: 1498–1506PubMedCrossRefGoogle Scholar
  27. 27.
    Le Riehe J, Atiba J, Ragaz J et al. (1989) The role of fine needle aspiration in determining the risk of breast cancer. In: Ragaz J, Ariel I (eds) High risk breast cancer-Diagnosis. Springer, Berlin Heidelberg New York, pp 120–137Google Scholar
  28. 28.
    Lesnick G, Perloff M, Korzun A et al. (1989) Neoadjuvant chemotherapy for stage III breast cancer - 5 year report of CALGB 7784. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 185–189Google Scholar
  29. 29.
    Lippman ME, Swain SM, Egan EF et al. (1989) Neoadjuvant chemotherapy in the combined modality approach of locally advanced non metastatic breast cancer. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 143–151Google Scholar
  30. 30.
    Ludvig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 319: 677–683CrossRefGoogle Scholar
  31. 31.
    Ludvig Breast Cancer Study Group (1989) Prolonged disease free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer. N Engl J Med 320: 491–496CrossRefGoogle Scholar
  32. 32.
    Morris DM, Aisner J, Elias EG et al. (1978) Mastectomy as an adjunct to combination chemotherapy. Arch Surg 113: 282–284PubMedCrossRefGoogle Scholar
  33. 33.
    Nissen-Meyer R, Host H, Kjellgren K et al. (1987) Neoadjuvant chemotherapy in breast cancer as single perioperative treatment and with supplementary longterm chemotherapy. In: Salmon S (ed) Adjuvant therapy of cancer V. Grune and Stratton, Orlando, pp 253–263Google Scholar
  34. 34.
    Papaioannou AN (1981) Perspective in cancer research: preoperative chemotherapy for operable solid tumors. Eur J Cancer 17: 963–969Google Scholar
  35. 35.
    Papaioannou AN, Lissaios B, Vasilaros S et al. (1983) Pre and postoperative endocrine treatment with or without postoperative radiotherapy for locally advanced breast cancer. Cancer 51: 1284–1290PubMedCrossRefGoogle Scholar
  36. 36.
    Papaioannou AN, Polychronis A, Kozonis JA et al. (1986) Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: a perspective study with at least 5 years followup. In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, New York, pp 142–148CrossRefGoogle Scholar
  37. 37.
    Pierce GB, Speers WC (1988) Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48: 1996–2004PubMedGoogle Scholar
  38. 38.
    Preoperative Breast Protocol (1988) NSABP B18, 32nd semi-annual meeting, Washington, D.C.Google Scholar
  39. 39.
    Ragaz J, Baird R, Rebbeck P et al. (1985) Neoadjuvant (preoperative) chemotherapy for breast cancer. Cancer 56: 719–724PubMedCrossRefGoogle Scholar
  40. 40.
    Ragaz J (1986) Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. NCI Monogr 1: 145–152PubMedGoogle Scholar
  41. 41.
    Ragaz J (1986) Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia trial. In: Ragaz J, Band P, Goldie J (eds) Preoperative (neoadjuvant) chemotherapy of cancer. Springer, Berlin Heidelberg New York, pp 85–94Google Scholar
  42. 42.
    Ragaz J, Band PR, Goldie JH (eds) (1986) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New YorkGoogle Scholar
  43. 43.
    Ragaz J, Manji M, Olivotto I et al. (1987) The role of mastectomy in preoperative (neoadjuvant) combined modality therapy of locally advanced breast cancer. Proc Am Soc Clin Oncol 6: 55Google Scholar
  44. 44.
    Ragaz J, Baird R, Goldie J (1989) Role of preoperative (neoadjuvant) therapy for breast cancer in stage I and II disease. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 157–169Google Scholar
  45. 45.
    Ragaz J, Manji M, Plenderleith IH et al. (1989) Analysis of the British Columbia study of preoperative (neoadjuvant) therapy of breast cancer in stage III disease. In: Jacquillat C, Weil M, Khayat D (eds) Neoadjuvant chemotherapy, 2nd international congress. Libbey, Paris, pp 249–259Google Scholar
  46. 46.
    Reiss M, Gamba-Vitallo C, Sartorelli AC (1986) Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 70: 201–218PubMedGoogle Scholar
  47. 47.
    Rocchi P, Ferreri AM, Simone G, Prod G (1987) Epirubicin induced differentiation of human neuroblastoma cells in vitro. Anticancer Res 7: 247–250PubMedGoogle Scholar
  48. 48.
    Rosen G (1986) Neoadjuvant chemotherapy for osteogenic sarcoma: a model for the treatment of other highly malignant neoplasms In: Ragaz J, Band PR, Goldie JH (eds) Preoperative (neoadjuvant) chemotherapy. Springer, Berlin Heidelberg New York, pp 148–158Google Scholar
  49. 49.
    Sachs L (1987) Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Res 47: 1981–1986PubMedGoogle Scholar
  50. 50.
    Sager Kern WH (1979) The diagnosis of breast cancer by fine needle aspiration smears. JAMA 241: 1125–1127CrossRefGoogle Scholar
  51. 51.
    Salter DR, Bassett AA (1981) A role of fine needle aspiration in reducing the number of unnecessary breast biopsies. Can J Surg 24: 311–313PubMedGoogle Scholar
  52. 52.
    Schwartz EL, Sartorelli AC (1982) Structure activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Cancer Res 42: 2651–2655PubMedGoogle Scholar
  53. 53.
    Simpson-Herren L, Sanford AH, Holmquist JP (1976) Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 60: 1749–1760PubMedGoogle Scholar
  54. 54.
    Thalmo W, Sand J, Marti J et al. (1984) Clinical and pathological findings in locally advanced breast cancer treated with Cyclophosphamide-Adriamycin-5-FU. Proc Am Soc Clin Oncol 3: 127Google Scholar
  55. 55.
    Tyzzer EE (1973) Factors in the production and growth of tumor metastases. J Med Res 28: 309Google Scholar
  56. 56.
    Wagener DJT, Blijham GH, Smeets JBE et al. (1985) Primary chemotherapy in cancer medicine. Liss, New YorkGoogle Scholar
  57. 57.
    Zajicek J (1974) Aspiration Biopsy and cytology pt.I: cytology of supradiaphragmatic organs. Karger, New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1991

Authors and Affiliations

  • J. Ragaz
    • 1
  1. 1.British Columbia Cancer AgencyVancouverCanada

Personalised recommendations